Science Will Win

Our Products
Grid_790x500.png
Grid_1000x450.jpg

Science Will Win

When science wins, we all win. Shop and share the collection, available in the U.S. only.
All profits from The Pfizer Store will be donated to charity.

Meet Ramcess Jean-Louis

Our People
Ram-Headshot_380x500_0.png
Ram-Headshot_1000x450.png

Meet Ramcess Jean-Louis

Ready to build on Pfizer’s commitment to Diversity, Equity, and Inclusion

The Facts About Pfizer and BioNTech’s COVID-19 Vaccine

Our Science
young_woman_getting_vaccinated_380x500_0.png
young_woman_getting_vaccinated_1000x450_0.jpg

The Facts About Pfizer and BioNTech’s COVID-19 Vaccine

The U.S. FDA authorization of the Pfizer-BioNTech COVID-19 vaccine for emergency use is a significant step forward in our fight against this pandemic.

Sickle Cell

Your Health
sickle-cell-trait-vs-sickle-cell-disease_790x500.png
sickle-cell-trait-vs-sickle-cell-disease_1000x450.jpg

Sickle Cell

Is there a difference between having sickle cell trait and sickle cell disease? Find out what steps to take if you or someone in your family is diagnosed with these conditions.

pfizer-logo
Your search for a clinical trial starts here.
Learn more about the process of joining a clinical trial and find a trial near you.

LEARN ABOUT OUR CLINICAL TRIAL FOR PEOPLE RECENTLY DIAGNOSED WITH COVID-19

Our Science
learn_about_our_clinical_trial_380x500_0.png
learn_about_our_clinical_trial_1000x450.jpg

LEARN ABOUT OUR CLINICAL TRIAL FOR PEOPLE RECENTLY DIAGNOSED WITH COVID-19

Do you have COVID-19? We are currently enrolling participants in a clinical trial for a potential oral treatment option.

Visit Our COVID-19 Hub

Your Health
GettyImages-1208505315_790x500.png
GettyImages-1208505315_1000x450.jpg

Visit Our COVID-19 Hub

What you need to know about the virus and updates on how Pfizer is responding to the crisis.

Latest News

BASEL, Switzerland and NEW YORK, September 9, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) accepted for review a supplemental New Drug Application (sNDA) for MYFEMBREE® (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) for the management of moderate to severe pain associated with endometriosis. The FDA set a target action date of May 6, 2022 for this sNDA under the…